Sunitha Nallur - Concepedia

Concepedia

Author

Sunitha Nallur

Yale University

Also Known As

Nallur, Sunitha, S Nallur, S. Nallur, S. V. Nallur, Sunitha Nallur, Sunitha V. Nallur

59

Publications

1.9K

Citations

18

H-Index

47

Concepts

All Affiliations

Yale University University of California, Los Angeles Harvard University New York University Heidelberg University

SN

About

Sunitha Nallur is an author at Yale University specializing in medicine, non-coding rna, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	876
2	Engineering	1	1	95
3	Natural Sciences	1	1	34
4	Biochemistry	1	1	34
5	Biology	1	1	46

Sunitha Nallur

×

20

Publications

1.9K

Citations

18

H-Index

	Year	Citations
A SNP in a <i>let-7</i> microRNA Complementary Site in the <i>KRAS</i> 3′ Untranslated Region Increases Non–Small Cell Lung Cancer Risk Lena J. Chin, Elena Ratner, Shuguang Leng, Cancer Research	2008	635
The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells Masaomi Kato, Trupti Paranjape, Robert L. Ullrich, Oncogene Cancer ResearchGene ExpressionRna BiologyMir-34 MicrornaC. Elegans	2009	237
A <i>KRAS</i> -Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk Elena Ratner, Lingeng Lu, Marta Boeke, Cancer Research	2010	139
A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis Trupti Paranjape, Helen Heneghan, Robert Lindner, The Lancet Oncology Genetic AnalysisBreast OncologyOncologyMedicineGenetics	2011	133
A <i>Let-7</i> MicroRNA SNP in the <i>KRAS</i> 3′UTR Is Prognostic in Early-Stage Colorectal Cancer Kim M. Smits, Trupti Paranjape, Sunitha Nallur, Clinical Cancer Research	2011	98
MicroRNA signatures differentiate melanoma subtypes Elcie Chan, Rajeshvari Patel, Sunitha Nallur, Cell Cycle EngineeringAggressive CancerPathologyMirna ArrayTumor Biology	2011	95
MicroRNA signatures differentiate uterine cancer tumor subtypes Elena Ratner, David Tuck, C. Richter, Gynecologic Oncology MedicinePathologyGynecologySmall RnaMicrorna Detection	2010	92
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer Elena Ratner, Florence K. Keane, Robert Lindner, Oncogene MedicineKras VariantPathologyGynecologyCancer Genomics	2011	82
miR-34 activity is modulated through 5′-end phosphorylation in response to DNA damage David W. Salzman, Kotoka Nakamura, Sunitha Nallur, Nature Communications	2016	80
Targeted resequencing of the microRNAome and 3′UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer X Chen, Trupti Paranjape, Carlos Stahlhut, Oncogene Altered PrevalenceEpithelial Ovarian CancerGeneticsMedicineGynecology	2014	48

Page 1